| A Study to Evaluate the Effect of Itraconazole and Rifampin on the Drug Levels of AR-LDD (BMS-986365) in Healthy Adult Male Participants (NCT07242781) | Celgene | 2025-12-15 |
| A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT06988488) | Celgene | 2025-10-07 |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease (NCT06808984) | Celgene | 2025-06-09 |
| A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity (NCT06782490) | Celgene | 2025-06-05 |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer (NCT06764485) | Celgene | 2025-03-13 |
| A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (NCT06425302) | Celgene | 2024-08-30 |
| Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment (NCT06535399) | Celgene | 2024-08-15 |
| Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (NCT06356129) | Celgene | 2024-06-19 |
| A Study to Evaluate the Safety, Tolerability, and Drug Levels of Orally Administered BMS-986368 in Healthy Participants, Healthy Elderly Participants, and Healthy Participants of Japanese Ethnicity (NCT06411730) | Celgene | 2024-05-31 |
| A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants (NCT06433505) | Celgene | 2024-05-30 |
| Study to Evaluate Safety, Drug Levels, Food and Relative Bioavailability of BMS-986365 in Healthy Adult Male Participants (NCT06417229) | Celgene | 2024-05-28 |
| A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants (NCT06363630) | Celgene | 2024-04-23 |
| A Study to Evaluate the Drug Levels of Mezigdomide in Adult Participants With Renal Impairment (NCT06318676) | Celgene | 2024-03-21 |
| A Study to Assess the Effects of Itraconazole, Food, and pH on the Drug Levels of BMS-986368 in Healthy Participants (NCT06170723) | Celgene | 2024-03-18 |
| A Study to Evaluate Alnuctamab in Combination With Mezigdomide in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT06163898) | Celgene | 2024-02-27 |
| A Study to Evaluate the Absorption, Metabolism, and Excretion of Orally Administered [14C]-BMS-986368 in Healthy Male Participants (NCT06227975) | Celgene | 2024-02-02 |
| A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation (NCT06045806) | Celgene | 2023-10-16 |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (NCT05519085) | Celgene | 2022-09-20 |
| Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis (NCT04991935) | Celgene | 2022-08-09 |
| Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (NCT04975997) | Celgene | 2022-06-23 |
| A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Japanese Participants With Eosinophilic Gastroenteritis (NCT05214768) | Celgene | 2022-03-04 |
| A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma (NCT04860466) | Celgene | 2022-01-20 |
| Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes (NCT04951778) | Celgene | 2021-12-02 |
| A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) (NCT04887857) | Celgene | 2021-12-01 |
| Safety Study to Evaluate Immune Response of Vaccines in Participants With Relapsing Forms of Multiple Sclerosis Who Receive Ozanimod Compared to Non-Pegylated Interferon (IFN)-β or No Disease Modifying Therapy (NCT05028634) | Celgene | 2021-11-11 |
| Connect® Lymphoma Disease Registry: A US-Based Prospective Observational Cohort Study (NCT04982471) | Celgene | 2021-11-03 |
| A Safety, Tolerability and Preliminary Efficacy Study of CC-90011 in Combination With Venetoclax and Azacitidine in R/R Acute Myeloid Leukemia and Treatment-naïve Participants Not Eligible for Intensive Therapy (NCT04748848) | Celgene | 2021-10-14 |
| Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma (NCT04882163) | Celgene | 2021-10-10 |
| Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma (NCT04975399) | Celgene | 2021-10-05 |
| Positron Emission Tomography (PET) Imaging Study to Evaluate Enzyme Availability in the Central Nervous System Before and After CC-97489 Administration in Healthy Participants (NCT05065541) | Celgene | 2021-09-24 |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma (NCT04884035) | Celgene | 2021-09-15 |
| A Study of CC-99677 in Participants With Active Ankylosing Spondylitis (NCT04947579) | Celgene | 2021-08-25 |
| Study to Evaluate Safety and Tolerability of Iberdomide (CC-220) in Participants With Kidney Impairment Compared to Participants With Normal Kidney Function (NCT04933747) | Celgene | 2021-08-12 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-99677 in Healthy Adult Japanese Participants. (NCT04958291) | Celgene | 2021-08-03 |
| A Study of CC-90011 and Comparators in Participants With Prostate Cancer (NCT04628988) | Celgene | 2021-07-28 |
| Study to Evaluate Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) (NCT04973280) | Celgene | 2021-07-26 |
| Study to Evaluate the Pressor Effect of Oral Tyramine During Ozanimod Treatment in Healthy Adult Participants (NCT04978298) | Celgene | 2021-07-19 |
| Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (NCT04789655) | Celgene | 2021-06-16 |
| Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma (NCT04855136) | Celgene | 2021-06-01 |
| A Study to Evaluate Safety and Effectiveness of Cendakimab (CC-93538) in Participants With Moderate to Severe Atopic Dermatitis (NCT04800315) | Celgene | 2021-05-14 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (NCT04717414) | Celgene | 2021-02-25 |
| A Study to Evaluate the Efficacy and Safety of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis (NCT04753697) | Celgene | 2021-02-22 |
| A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM (NCT04730505) | Celgene | 2021-02-04 |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants (NCT04839809) | Celgene | 2021-01-19 |
| A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects (NCT04702464) | Celgene | 2021-01-12 |
| A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (NCT04434196) | Celgene | 2020-12-21 |
| A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod (NCT04639115) | Celgene | 2020-12-18 |
| Revlimid® Capsules General Drug Use-results Surveillance (Relapsed or Refractory FL and MZL) (NCT04618081) | Celgene | 2020-12-17 |
| Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects (NCT04655898) | Celgene | 2020-12-16 |
| Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment (NCT04573582) | Celgene | 2020-11-13 |
| A Dose Finding and Safety Study of CC-220, Alone and in Combination With an Anti-CD20 Monoclonal Antibody (mAb) in Subjects With Relapsed or Refractory Lymphomas (NCT04464798) | Celgene | 2020-11-11 |
| A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants (NCT04560738) | Celgene | 2020-10-15 |
| A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects (NCT04528290) | Celgene | 2020-10-07 |
| A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants (NCT04718636) | Celgene | 2020-09-30 |
| A Study to Evaluate the Pharmacokinetics of Single Oral Doses of Ozanimod in Healthy Adult Chinese Subjects (NCT04211558) | Celgene | 2020-08-12 |
| A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia (NCT04336982) | Celgene | 2020-08-05 |
| A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers (NCT04350463) | Celgene | 2020-07-14 |
| A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (NCT04245839) | Celgene | 2020-07-14 |
| A Study of CC-90010 in Combination With Temozolomide With or Without Radiation Therapy in Participants With Newly Diagnosed Glioblastoma (NCT04324840) | Celgene | 2020-07-10 |
| Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer (NCT04428788) | Celgene | 2020-06-22 |
| Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects (NCT04373187) | Celgene | 2020-06-22 |
| A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM) (NCT04196491) | Celgene | 2020-05-27 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CC-97489 in Healthy Adult Participants (NCT05099822) | Celgene | 2020-03-13 |
| A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677 (NCT04268394) | Celgene | 2020-03-13 |
| A Study to Evaluate the Metabolism and Excretion of [14C]-CC-90009 in Healthy Male Subjects (NCT04297124) | Celgene | 2020-03-11 |
| Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated With Ozanimod (RPC-1063) (NCT04140305) | Celgene | 2020-01-16 |
| CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma (NCT04047303) | Celgene | 2020-01-02 |
| Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and Metformin (NCT04231435) | Celgene | 2019-12-18 |
| A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea (NCT04036448) | Celgene | 2019-11-28 |
| Study of Safety & PK of Luspatercept (ACE-536) in Pediatric Participants With Beta (β)-Thalassemia (NCT04143724) | Celgene | 2019-11-07 |
| Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma (NCT04089527) | Celgene | 2019-10-24 |
| Relative Bioavailability and PPI Effects of CC-92480 Test and Reference Formulations in Healthy Subjects (NCT04211545) | Celgene | 2019-10-21 |
| Japanese Pharmacokinetic Bridging Study for CC-93538 (NCT04096105) | Celgene | 2019-10-14 |
| Bioavailability of Enasidenib (CC-90007) Sprinkle Formulation Relative to the Reference Tablet Formulation and Effect of Food on the Pharmacokinetics of Sprinkle Formulation in Healthy Adults (NCT04310527) | Celgene | 2019-10-09 |
| Drug Interaction Study of the Effect on Cyclosporine on Ozanimod and Major Active Metabolites (NCT04149678) | Celgene | 2019-10-04 |
| A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) (NCT03989414) | Celgene | 2019-09-30 |
| An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (NCT03952039) | Celgene | 2019-09-09 |
| A Pharmacokinetics and Tolerability Study of Fedratinib in Subjects With Moderate and Severe Hepatic Impairment (NCT03983161) | Celgene | 2019-09-04 |
| Pharmacogenetics Sampling of the CC-90007-CP-003 Study Cohort (NCT04097704) | Celgene | 2019-09-04 |
| A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma (NCT04036461) | Celgene | 2019-08-26 |
| Study to Evaluate the Efficacy and Safety of CC-90001 in Participants With Non-alcoholic Steatohepatitis (NASH) and Liver Fibrosis (NCT04048876) | Celgene | 2019-08-14 |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials (NCT04064060) | Celgene | 2019-08-12 |
| A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer (NCT03906526) | Celgene | 2019-07-03 |
| Effect of Rifampin and Efavirenz on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects (NCT03983239) | Celgene | 2019-06-21 |
| To Evaluate Efficacy and Long-term Safety of Ozanimod in Japanese Subjects With Moderately to Severely Active Ulcerative Colitis (NCT03915769) | Celgene | 2019-06-03 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion (NCT03900715) | Celgene | 2019-05-20 |
| A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) (NCT03930953) | Celgene | 2019-05-20 |
| Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (NCT03651128) | Celgene | 2019-04-16 |
| A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects (NCT03958864) | Celgene | 2019-04-04 |
| A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (NCT03755518) | Celgene | 2019-03-27 |
| A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma (NCT03647124) | Celgene | 2019-03-13 |
| A Safety, Tolerability and Preliminary Efficacy Evaluation of CC-90011 Given in Combination With Cisplatin and Etoposide in Subjects With First Line, Extensive Stage Small Cell Lung Cancer (NCT03850067) | Celgene | 2019-03-12 |
| A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers (NCT03783403) | Celgene | 2019-03-01 |
| Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects (NCT03824678) | Celgene | 2019-02-13 |
| ISTODAX® for Intravenous Infusion Drug Use Results Survey- Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT03742921) | Celgene | 2019-02-04 |
| A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (NCT03682536) | Celgene | 2019-01-02 |
| Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects (NCT03803644) | Celgene | 2018-12-21 |
| An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma (NCT03601078) | Celgene | 2018-12-13 |
| A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects (NCT03742882) | Celgene | 2018-12-06 |
| Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma (NCT03703375) | Celgene | 2018-11-06 |